earnings
Elevance Health Shares Jump as Q2 Profit Crushes Estimates, Full-Year Outlook Raised
Elevance Health shares jumped after Q2 profit beat estimates and the company raised its full-year outlook.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Wed · 15 Jul
earnings
Elevance Health shares jumped after Q2 profit beat estimates and the company raised its full-year outlook.
Markets open original ↗
regulation
The FDA approved a weekly subcutaneous formulation of lecanemab for Alzheimer's disease.
Markets open original ↗
partnership
Airbus is reportedly set to win A330 jet orders from Flynas and Condor.
Markets open original ↗
partnership
Northrop Grumman and Airbus signed an agreement to explore a Triton role for NATO.
Markets open original ↗
regulation
Roche's Gazyva received FDA priority review for a kidney disease indication.
Markets open original ↗